Supplementary data for:

Functional characterisation of a *PBX1 de novo* **missense variant identified in a patient with syndromic congenital heart disease**

Dimuthu Alankarage¹, Justin Szot¹, Nick Pachter^{2,3}, Anne Slavotinek^{4,5}, Licia Selleri^{5,6}, Joseph Shieh ^{4,5}, David Winlaw ^{1,7,8}, Eleni Giannoulatou ^{1,9}, Gavin Chapman ^{1, 9}, Sally L. Dunwoodie 1,9*

¹ Victor Chang Cardiac Research Institute, Darlinghurst, Sydney, Australia; ² Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Australia; ³ University of Western Australia, Perth, Australia; ⁴ Division of Medical Genetics, Department of Pediatrics, University of California San Francisco, CA, USA; ⁵ Institute of Human Genetics, University of California San Francisco, CA, USA; ⁶ Program in Craniofacial Biology, Department of Orofacial Sciences and Department of Anatomy, University of California San Francisco, CA, USA; ⁷ Heart Centre for Children, The Children's Hospital at Westmead, Sydney, Australia; ⁸ Faculty of Medicine and Health, University of Sydney, Sydney, Australia; ⁹ Faculty of Medicine, University of New South Wales, Sydney, Australia.

Corresponding author

* Corresponding author: Tel: +61 2 9295 8613, E-mail: s.dunwoodie@victorchang.edu.au

Supplementary tables

Supplementary table 1: Rare, damaging variants that segregate with disease in family 3467.

As the proband has sporadic CHD, variants that were *de novo*, recessive and compound heterozygous were considered. They were filtered by minor allele frequency (<0.01) and by predicted pathogenicity by CADD-PHRED (≥15) and Polyphen-HVAR (≥0.446). Two *de novo* variants in genes *PBX1* and *ESPNL* as well as compound heterozygous variants in *OBSCN* and *ATRN* were identified. †Relative to hg19. MAF: Minor Allele Frequency, with respect to gnomAD. PolyPhen2-HVAR: 0 (benign) – 1 (probably damaging). CADD-PHRED: 1-99; \geq 10 (top 10% of deleterious mutation); \geq 20 (top 1% of deleterious mutation).

Supplementary table 2. Phenotype details of patients reported with pathogenic, single gene *PBX1* variants. Patients with missense variants are presented first, followed by patients with loss-of-function alleles.

Missense

LOF

(^aSlavotinek et al., 2017 (1), ^bEozenou et al., 2019 (2), °Current manuscript, °Riedhammer et al., 2017 (3), ^fHeidet et al., 2017 (4), ^gLe Tanno et al., 2017 (5)). ^dOther include phenotypes that do not fall within any other category.

Supplementary figures

Supplementary figure 1. (A) Amino acid sequence conservation between human and mouse PBX1. The 430 amino acid protein is completely conserved between the two species. Residue R184 is indicated in *red*. (B) Sanger sequencing of the founder PBX1-R184P mouse created by Crispr-Cas9. Nucleotide change *Pbx1*:c.551G>C is observed in the founder and not present in wild-type, unaltered mice.

Supplementary figure 2. Mendelian ratios observed in embryos derived from matings between heterozygous males and heterozygous females at six stages of development (E11.5, E13.5, E14.5, E15.5, E17.5 and birth). Chi-square test was performed to detect deviations from expected versus observed numbers of embryos for wild-type (+/+), heterozygous (+/R184P) and homozygous (R184P/R184P) genotypes.

Supplementary figure 3. Embryonic body weights and body volumes of the wild-type, heterozygous and homozygous embryos at four stages of development (E13.5, E14.5, E15.5 and E17.5). (n ≥ 12 per stage, * p <0.05, ** p <0.01, *** p <0.001)

Supplementary figure 4. R184P/R184P homozygous embryos exhibited abnormal adrenal glands, spleen and thymi. Adrenal glands and spleen were aplastic. Thymi were absent or ectopic. Defects in these organs were not observed in wild-type or heterozygous embryos. (n ≥ 15 per stage).

Supplementary figure 5. Umbilical hernia was observed in wild-type, heterozygous and homozygous embryos at E13.5, E14.5 and E15.5. At E17.5, wild-type embryos no longer exhibited umbilical hernia. 12.5% of heterozygous embryos had umbilical hernia. All homozygous embryos continued to exhibit umbilical hernia. Subcutaneous oedema was observed in 27% of heterozygous embryos at E13.5, 12% at E14.5, 10% at E15.5, and 12.5% at E17.5. All homozygous embryos displayed subcutaneous oedema at all stages analysed. This phenotype was not observed in any wild-type embryos analysed. (n ≥ 15 per stage).

Supplementary figure 6. Eyes stay open in wild-type, heterozygous and homozygous embryos at E13.5, E14.5 and E15.5. At E17.5, wild-type and heterozygous embryos have closed eyes. At this stage, the homozygous embryos continue to display open eyes. At E13.5, all wild-type, heterozygous and homozygous embryos had unfused secondary palatal shelves. At E14.5, 13% of wild-type and 12% of heterozygous embryos had fused palatal shelves. At E15.5 and at E17.5, all wild-type and heterozygous embryos had fused palatal shelves. Homozygous embryos at these stages continued to exhibit unfused palatal shelves. In homozygous embryos, trachea were atretic at all stages. The larynx

was atretic until E17.5. In heterozygous embryos, 12% had atretic larynx at E13.5 and E14.5, and were normal at E15.5 and E17.5. Atretic larynx were observed in 13% of wild-type embryos at E14.5 and at no other stages. (n ≥ 14 per stage).

References

1 Slavotinek, A., Risolino, M., Losa, M., Cho, M.T., Monaghan, K.G., Schneidman-Duhovny, D., Parisotto, S., Herkert, J.C., Stegmann, A.P.A., Miller, K. *et al.* (2017) De novo, deleterious sequence variants that alter the transcriptional activity of the homeoprotein PBX1 are associated with intellectual disability and pleiotropic developmental defects. *Human molecular genetics*, **26**, 4849-4860.

2 Eozenou, C., Bashamboo, A., Bignon-Topalovic, J., Merel, T., Zwermann, O., Lourenco, D., Lottmann, H., Lichtenauer, U., Rojo, S., Beuschlein, F. *et al.* (2019) The TALE homeodomain of PBX1 is involved in human primary testis-determination. *Human mutation*, in press.

3 Riedhammer, K.M., Siegel, C., Alhaddad, B., Montoya, C., Kovacs-Nagy, R., Wagner, M., Meitinger, T. and Hoefele, J. (2017) Identification of a Novel Heterozygous De Novo 7-bp Frameshift Deletion in PBX1 by Whole-Exome Sequencing Causing a Multi-Organ Syndrome Including Bilateral Dysplastic Kidneys and Hypoplastic Clavicles. *Frontiers in pediatrics*, **5**, 251.

4 Heidet, L., Moriniere, V., Henry, C., De Tomasi, L., Reilly, M.L., Humbert, C., Alibeu, O., Fourrage, C., Bole-Feysot, C., Nitschke, P. *et al.* (2017) Targeted Exome Sequencing Identifies PBX1 as Involved in Monogenic Congenital Anomalies of the Kidney and Urinary Tract. *Journal of the American Society of Nephrology : JASN*, **28**, 2901-2914.

5 Le Tanno, P., Breton, J., Bidart, M., Satre, V., Harbuz, R., Ray, P.F., Bosson, C., Dieterich, K., Jaillard, S., Odent, S. *et al.* (2017) PBX1 haploinsufficiency leads to syndromic congenital anomalies of the kidney and urinary tract (CAKUT) in humans. *Journal of medical genetics*, **54**, 502-510.